We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , Abbott Laboratories (ABT - Free Report) , Qualcomm Inc. (QCOM - Free Report) , Johnson & Johnson (JNJ - Free Report) and BHP Group Ltd. (BHP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for JPMorgan, Abbott Labs and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Abbott Laboratories and Qualcomm Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of JPMorgan have outperformed the Zacks Banks - Major Regional industry over the past year (+29.8% vs. +17.7%). High interest rates, buyouts, global expansion efforts and decent loan demand will aid net interest income (NII), though rising funding costs will weigh on it.
According to the Zacks analyst estimates for NII (managed) and loans imply a CAGR of 9.8% and 7.2%, respectively, by 2025. Aided by solid earnings strength and balance sheet, it will be able to sustain capital distributions. Despite visibility of some greenshoots in the investment banking (IB) business, IB fees are less likely to improve soon.
This, along with the volatile nature of the capital markets business and high mortgage rates, will likely hamper fee income growth. Owing to these challenges, we expect total non-interest income (managed) to witness a CAGR of just 3.6% by 2025. Mounting costs are a woe and we expect it to rise 11% in 2023.
Abbott shares have outperformed the Zacks Medical - Products industry over the past year (+2.1% vs. -0.1%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets, the Zacks analyst expects Abbott to register a sales CAGR of nearly 6% through fiscal 2025.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China continues to impede overall growth in Nutrition.
Shares of Qualcomm have outperformed the Zacks Wireless Equipment industry over the past year (+24.6% vs. +9.2%). The company is well poised to benefit from solid 5G traction, greater visibility and a diversified revenue stream. Strength in the snapdragon portfolio is an additional tailwind as exemplified by the multi-year.
Apple deals for 5G modems for iPhones. It is focusing on a seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge. Qualcomm is also witnessing solid momentum in IoT.
However, it reported relatively soft fourth-quarter fiscal 2023 results owing to a challenging macroeconomic environment, inflationary pressures and soft recovery in China, resulting in lower-than-expected demand and elevated inventory levels.
Weakness in the smartphone industry and cautious client approach are weighing on margins. Rising geopolitical conflicts and high debt burden remain headwinds.
Other noteworthy reports we are featuring today include Johnson & Johnson and BHP Group Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP
For Immediate Release
Chicago, IL – December 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , Abbott Laboratories (ABT - Free Report) , Qualcomm Inc. (QCOM - Free Report) , Johnson & Johnson (JNJ - Free Report) and BHP Group Ltd. (BHP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for JPMorgan, Abbott Labs and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Abbott Laboratories and Qualcomm Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of JPMorgan have outperformed the Zacks Banks - Major Regional industry over the past year (+29.8% vs. +17.7%). High interest rates, buyouts, global expansion efforts and decent loan demand will aid net interest income (NII), though rising funding costs will weigh on it.
According to the Zacks analyst estimates for NII (managed) and loans imply a CAGR of 9.8% and 7.2%, respectively, by 2025. Aided by solid earnings strength and balance sheet, it will be able to sustain capital distributions. Despite visibility of some greenshoots in the investment banking (IB) business, IB fees are less likely to improve soon.
This, along with the volatile nature of the capital markets business and high mortgage rates, will likely hamper fee income growth. Owing to these challenges, we expect total non-interest income (managed) to witness a CAGR of just 3.6% by 2025. Mounting costs are a woe and we expect it to rise 11% in 2023.
(You can read the full research report on JPMorgan here >>>)
Abbott shares have outperformed the Zacks Medical - Products industry over the past year (+2.1% vs. -0.1%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets, the Zacks analyst expects Abbott to register a sales CAGR of nearly 6% through fiscal 2025.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China continues to impede overall growth in Nutrition.
(You can read the full research report on Abbott here >>>)
Shares of Qualcomm have outperformed the Zacks Wireless Equipment industry over the past year (+24.6% vs. +9.2%). The company is well poised to benefit from solid 5G traction, greater visibility and a diversified revenue stream. Strength in the snapdragon portfolio is an additional tailwind as exemplified by the multi-year.
Apple deals for 5G modems for iPhones. It is focusing on a seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge. Qualcomm is also witnessing solid momentum in IoT.
However, it reported relatively soft fourth-quarter fiscal 2023 results owing to a challenging macroeconomic environment, inflationary pressures and soft recovery in China, resulting in lower-than-expected demand and elevated inventory levels.
Weakness in the smartphone industry and cautious client approach are weighing on margins. Rising geopolitical conflicts and high debt burden remain headwinds.
(You can read the full research report on QUALCOMM here >>>)
Other noteworthy reports we are featuring today include Johnson & Johnson and BHP Group Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.